OrbiMed — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Convergent provides an AI simulation platform for enterprise training and skill development.
AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB
Co-investorsTechstarsAndreessen HorowitzRA Capital
BiotechCambridge, US
Philip Kantoff(Executive Officer, Director)Neil Bander(Executive Officer, Director)Eric Sullivan(Executive Officer)Alexander Brown(Executive Officer)
BoardJake Simson(Director)inTal Zaks(Director)
Co-investorsInvusRA Capital
Evozyne is an AI-native biotech that designs de novo therapeutic proteins using EvoGen, a machine learning engine, and EvoLab, a high-throughput experimental facility that synthesizes and tests candidate proteins.
AI & Machine LearningBiotechDeep TechChicago, US
Aris Theologis(Executive Officer, Director)Darien Parhad(Executive Officer)Patrick J. Morris(Executive Officer, Director)Rama Ranganathan(Executive Officer, Director)
BoardJeffrey S. Aronin(Director)Antonio Gracias(Director)in
Co-investorsParagon Biosciences LLCFidelity InvestmentsNVenturesNVIDIAValor Equity Partners
MinervaX is a clinical-stage biotech company developing a prophylactic vaccine against Group B Streptococcus, with a lead candidate (AlpN GBS) in clinical trials for use in pregnancy and older adults.
BiotechHealthtech
Co-investorsAdjuvant CapitalIndustrifondenLU InnovationPureos BioventuresSanofi VenturesSunstone Capital+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.